DE69632353T2 - Hochreines Albumin, durch ein mehrstufiges Verfahren hergestellt - Google Patents
Hochreines Albumin, durch ein mehrstufiges Verfahren hergestellt Download PDFInfo
- Publication number
- DE69632353T2 DE69632353T2 DE69632353T DE69632353T DE69632353T2 DE 69632353 T2 DE69632353 T2 DE 69632353T2 DE 69632353 T DE69632353 T DE 69632353T DE 69632353 T DE69632353 T DE 69632353T DE 69632353 T2 DE69632353 T2 DE 69632353T2
- Authority
- DE
- Germany
- Prior art keywords
- albumin
- less
- preparation according
- ion content
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 102000009027 Albumins Human genes 0.000 title claims abstract description 290
- 108010088751 Albumins Proteins 0.000 title claims abstract description 290
- 238000000034 method Methods 0.000 title claims abstract description 69
- 230000008569 process Effects 0.000 title abstract description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 43
- -1 ammonium ions Chemical class 0.000 claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 31
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 24
- 229930195729 fatty acid Natural products 0.000 claims description 24
- 238000009472 formulation Methods 0.000 claims description 20
- 239000012535 impurity Substances 0.000 claims description 15
- 229910052782 aluminium Inorganic materials 0.000 claims description 11
- 241000235648 Pichia Species 0.000 claims description 8
- 238000002835 absorbance Methods 0.000 claims description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
- 150000002402 hexoses Chemical class 0.000 claims description 6
- 241000235070 Saccharomyces Species 0.000 claims description 5
- 230000036252 glycation Effects 0.000 claims description 5
- 229910052742 iron Inorganic materials 0.000 claims description 5
- 241000235649 Kluyveromyces Species 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 4
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 3
- 229910001431 copper ion Inorganic materials 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000001698 pyrogenic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 claims 1
- 229910001437 manganese ion Inorganic materials 0.000 claims 1
- 238000000108 ultra-filtration Methods 0.000 abstract description 38
- 239000000463 material Substances 0.000 abstract description 28
- 238000005341 cation exchange Methods 0.000 abstract description 26
- 238000010828 elution Methods 0.000 abstract description 13
- 239000012634 fragment Substances 0.000 abstract description 12
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 238000001042 affinity chromatography Methods 0.000 abstract description 10
- 229910021645 metal ion Inorganic materials 0.000 abstract description 7
- 238000005227 gel permeation chromatography Methods 0.000 abstract description 6
- 239000011347 resin Substances 0.000 abstract description 6
- 229920005989 resin Polymers 0.000 abstract description 6
- 150000003573 thiols Chemical class 0.000 abstract description 6
- 238000005571 anion exchange chromatography Methods 0.000 abstract description 5
- 229920000642 polymer Polymers 0.000 abstract description 5
- ILOJFJBXXANEQW-UHFFFAOYSA-N aminooxy(phenyl)borinic acid Chemical compound NOB(O)C1=CC=CC=C1 ILOJFJBXXANEQW-UHFFFAOYSA-N 0.000 abstract description 4
- 239000000356 contaminant Substances 0.000 abstract description 3
- 102000003839 Human Proteins Human genes 0.000 abstract description 2
- 108090000144 Human Proteins Proteins 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 abstract description 2
- 239000001045 blue dye Substances 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 80
- 239000011159 matrix material Substances 0.000 description 73
- 102000008100 Human Serum Albumin Human genes 0.000 description 46
- 108091006905 Human Serum Albumin Proteins 0.000 description 46
- 239000000872 buffer Substances 0.000 description 43
- 238000000855 fermentation Methods 0.000 description 36
- 230000004151 fermentation Effects 0.000 description 36
- 239000000047 product Substances 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000002609 medium Substances 0.000 description 23
- 238000005349 anion exchange Methods 0.000 description 21
- 239000000975 dye Substances 0.000 description 21
- 150000003839 salts Chemical class 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 150000004665 fatty acids Chemical class 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000499 gel Substances 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000011068 loading method Methods 0.000 description 14
- 239000012528 membrane Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 238000004587 chromatography analysis Methods 0.000 description 13
- 238000004140 cleaning Methods 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 13
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 12
- 239000004365 Protease Substances 0.000 description 12
- 239000012071 phase Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 229920000936 Agarose Polymers 0.000 description 11
- 238000011026 diafiltration Methods 0.000 description 11
- 239000012465 retentate Substances 0.000 description 11
- 238000005406 washing Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000009102 absorption Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 239000012086 standard solution Substances 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 238000005530 etching Methods 0.000 description 6
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 6
- 235000017281 sodium acetate Nutrition 0.000 description 6
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 description 5
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 5
- 239000005695 Ammonium acetate Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 5
- 235000019257 ammonium acetate Nutrition 0.000 description 5
- 229940043376 ammonium acetate Drugs 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011210 chromatographic step Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000001632 sodium acetate Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- VZPXDCIISFTYOM-UHFFFAOYSA-K trisodium;1-amino-4-[4-[[4-chloro-6-(3-sulfonatoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfonatoanilino]-9,10-dioxoanthracene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC(C=C1S([O-])(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S([O-])(=O)=O)=C1 VZPXDCIISFTYOM-UHFFFAOYSA-K 0.000 description 4
- ZHTJVFJXNTXXOV-UHFFFAOYSA-N 1-(5-acetyl-2,6-dimethyl-1,2-dihydropyridin-3-yl)ethanone Chemical compound CC1NC(C)=C(C(C)=O)C=C1C(C)=O ZHTJVFJXNTXXOV-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 101100330290 Arabidopsis thaliana CS26 gene Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000005700 Putrescine Substances 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003816 axenic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- YKCWQPZFAFZLBI-UHFFFAOYSA-N cibacron blue Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC=C1S(O)(=O)=O YKCWQPZFAFZLBI-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 239000010439 graphite Substances 0.000 description 3
- 229910002804 graphite Inorganic materials 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000005297 pyrex Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 235000011008 sodium phosphates Nutrition 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- CKNYEUXAXWTAPK-UHFFFAOYSA-N 4-octoxy-4-oxobutanoic acid Chemical compound CCCCCCCCOC(=O)CCC(O)=O CKNYEUXAXWTAPK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 101800001415 Bri23 peptide Proteins 0.000 description 2
- 101800000655 C-terminal peptide Proteins 0.000 description 2
- 102400000107 C-terminal peptide Human genes 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920002271 DEAE-Sepharose Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- 108010058643 Fungal Proteins Proteins 0.000 description 2
- 241001138401 Kluyveromyces lactis Species 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 2
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 2
- 241000320412 Ogataea angusta Species 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 241000235013 Yarrowia Species 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000011082 depyrogenation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000013541 low molecular weight contaminant Substances 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229940116191 n-acetyltryptophan Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- 238000012807 shake-flask culturing Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DIRRKLFMHQUJCM-UHFFFAOYSA-N (2-aminophenyl)boronic acid Chemical compound NC1=CC=CC=C1B(O)O DIRRKLFMHQUJCM-UHFFFAOYSA-N 0.000 description 1
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- RTLULCVBFCRQKI-UHFFFAOYSA-N 1-amino-4-[3-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-sulfoanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=1)=CC=C(S(O)(=O)=O)C=1NC1=NC(Cl)=NC(Cl)=N1 RTLULCVBFCRQKI-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101000849579 Arabidopsis thaliana 30S ribosomal protein S13, chloroplastic Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010023063 Bacto-peptone Proteins 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001508787 Citeromyces Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010071241 Factor XIIa Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
- 101000742143 Homo sapiens Prenylated Rab acceptor protein 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000235650 Kluyveromyces marxianus Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000221479 Leucosporidium Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010038049 Mating Factor Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102100038619 Prenylated Rab acceptor protein 1 Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 241000235003 Saccharomycopsis Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000509404 Scorpaenichthys marmoratus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000228389 Sporidiobolus Species 0.000 description 1
- 241000235006 Torulaspora Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000235033 Zygosaccharomyces rouxii Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 238000005885 boration reaction Methods 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011035 continuous diafiltration Methods 0.000 description 1
- 238000011217 control strategy Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- DKTXXUNXVCHYDO-UHFFFAOYSA-N phenoxyborinic acid Chemical compound OBOC1=CC=CC=C1 DKTXXUNXVCHYDO-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 229940079710 sodium acetyltryptophanate Drugs 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- UQSHZBSQKMVQBS-UHFFFAOYSA-M sodium;2-acetamido-3-(1h-indol-3-yl)propanoate Chemical compound [Na+].C1=CC=C2C(CC(NC(=O)C)C([O-])=O)=CNC2=C1 UQSHZBSQKMVQBS-UHFFFAOYSA-M 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/378,859 US5728553A (en) | 1992-09-23 | 1995-05-25 | High purity albumin and method of producing |
| US378859 | 1995-05-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69632353D1 DE69632353D1 (de) | 2004-06-03 |
| DE69632353T2 true DE69632353T2 (de) | 2005-05-04 |
Family
ID=23494845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69611445T Expired - Lifetime DE69611445T2 (de) | 1995-05-25 | 1996-02-29 | Verfahren zum herstellen von höchstreinem albumin |
| DE69632353T Expired - Lifetime DE69632353T2 (de) | 1995-05-25 | 1996-02-29 | Hochreines Albumin, durch ein mehrstufiges Verfahren hergestellt |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69611445T Expired - Lifetime DE69611445T2 (de) | 1995-05-25 | 1996-02-29 | Verfahren zum herstellen von höchstreinem albumin |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US5728553A (enExample) |
| EP (2) | EP1031578B1 (enExample) |
| JP (4) | JP4040088B2 (enExample) |
| KR (2) | KR100566606B1 (enExample) |
| CN (4) | CN100443499C (enExample) |
| AT (2) | ATE265469T1 (enExample) |
| AU (1) | AU698409B2 (enExample) |
| CA (1) | CA2220923C (enExample) |
| DE (2) | DE69611445T2 (enExample) |
| DK (2) | DK1031578T3 (enExample) |
| ES (2) | ES2219257T3 (enExample) |
| GR (1) | GR3035651T3 (enExample) |
| MX (1) | MX9709108A (enExample) |
| PT (2) | PT828759E (enExample) |
| WO (1) | WO1996037515A1 (enExample) |
Families Citing this family (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| DE19538625C2 (de) * | 1995-10-17 | 1999-08-12 | Sartorius Gmbh | Verfahren zur Abtrennung von Albumin aus Serum durch Membranionenaustauschchromatographie |
| GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| PT889949E (pt) * | 1996-03-13 | 2003-10-31 | Delta Biotechnology Ltd | Controlo de fermentacao |
| GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
| AU2007200859A1 (en) * | 1999-01-30 | 2007-03-22 | Novozymes Delta Limited | Process |
| FR2792650B1 (fr) * | 1999-04-20 | 2003-02-28 | Oreal | Equivalent de peau agee, son procede de preparation et son utilisation |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| EP1514556B1 (en) * | 2000-02-08 | 2011-08-10 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| US8632785B2 (en) | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| US20060269575A1 (en) * | 2000-02-08 | 2006-11-30 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions formulated with recombinant albumin |
| US7780967B2 (en) | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050100991A1 (en) * | 2001-04-12 | 2005-05-12 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CN100553636C (zh) | 2000-08-04 | 2009-10-28 | Dmi生物科学公司 | 二酮基哌嗪和包含它们的组合物的使用方法 |
| CA2395587C (en) * | 2000-10-24 | 2012-09-18 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Method of monomerizing human serum albumin polymers |
| JP4798833B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | 加熱処理工程を含むヒト血清アルブミンの製造方法 |
| JP4798832B2 (ja) | 2000-10-24 | 2011-10-19 | 一般財団法人化学及血清療法研究所 | ヒト血清アルブミン多量体の除去方法 |
| US7507413B2 (en) * | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| BR0210386A (pt) * | 2001-06-13 | 2004-09-14 | Taurus Hsa Llc | Purificação de albumina de soro humano |
| ITBO20010426A1 (it) * | 2001-07-06 | 2003-01-06 | Alfa Wassermann Spa | Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico |
| JP2003040798A (ja) * | 2001-07-26 | 2003-02-13 | Nihon Pharmaceutical Co Ltd | 低アルミニウム含有アルブミン製剤およびその製造法 |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| AU2002351412B2 (en) * | 2001-12-21 | 2010-05-20 | Exelixis Patent Company Llc | Modulators of LXR |
| CA2484556A1 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20080167238A1 (en) * | 2001-12-21 | 2008-07-10 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| EP2990417A1 (en) | 2001-12-21 | 2016-03-02 | Human Genome Sciences, Inc. | Albumin insulin fusion protein |
| GB0217033D0 (en) | 2002-07-23 | 2002-08-28 | Delta Biotechnology Ltd | Gene and polypeptide sequences |
| JP4674317B2 (ja) * | 2002-10-02 | 2011-04-20 | ディエムアイ アクイジション コーポレイション | 疾病の判定および監視 |
| EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| EP2517718B1 (en) | 2003-05-15 | 2016-03-02 | Ampio Pharmaceuticals, Inc. | Treatment of T-cell mediated diseases |
| US8013611B2 (en) * | 2006-07-14 | 2011-09-06 | Reserve Power Cell, Llc | Vehicle battery product and battery monitoring system |
| US7339347B2 (en) * | 2003-08-11 | 2008-03-04 | Reserve Power Cell, Llc | Apparatus and method for reliably supplying electrical energy to an electrical system |
| GB0329681D0 (en) | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Gene expression technique |
| US9057061B2 (en) * | 2003-12-23 | 2015-06-16 | Novozymes Biopharma Dk A/S | Gene expression technique |
| GB0329722D0 (en) * | 2003-12-23 | 2004-01-28 | Delta Biotechnology Ltd | Modified plasmid and use thereof |
| BRPI0418304A (pt) * | 2004-01-07 | 2007-05-02 | Trimeris Inc | peptìdeo sintético, uso do mesmo, composição farmacêutica, seqüência de nucleotìdeos, e, métodos para inibição da transmissão de hiv para uma célula, para inibição da fusão de hiv, e para tratamento de um indivìduo infectado com hiv |
| EP1710250B1 (en) | 2004-01-20 | 2009-04-15 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Method for preparing human serum albumin through heat-treatment in presence of divalent cation |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US20060199280A1 (en) * | 2005-03-03 | 2006-09-07 | David Bar-Or | Quantification of proteins |
| US7598700B2 (en) * | 2005-03-30 | 2009-10-06 | Reserve Power Cell, Llc | Tamper resistant battery and battery warranty and performance tracking system |
| MY144344A (en) * | 2005-04-08 | 2011-09-15 | Ciba Holding Inc | Adsorbents comprising anthraquinone dye-ligands for the separation of biological materials |
| DE102005023155A1 (de) | 2005-05-13 | 2006-11-16 | Albutec Gmbh | Albuminlösung |
| US8323666B2 (en) | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| GB0518460D0 (en) * | 2005-09-09 | 2005-10-19 | Univ Nottingham Trent | Protein assay |
| EP1989220B1 (en) | 2006-02-02 | 2011-12-14 | Trimeris, Inc. | Hiv fusion inhibitor peptides with improved biological properties |
| JP2007284425A (ja) * | 2006-03-20 | 2007-11-01 | Nokodai Tlo Kk | タンパク質の精製方法 |
| CA2654055A1 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US9139611B2 (en) | 2006-07-13 | 2015-09-22 | Novozymes Biopharma Dk A/S | Process for preparing particles of proteinaceous material |
| ATE524493T1 (de) | 2006-07-24 | 2011-09-15 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteine |
| US10829733B2 (en) * | 2007-01-04 | 2020-11-10 | Biolamina Ab | Composition and method for enabling proliferation of pluripotent human stem cells |
| CN101678125A (zh) * | 2007-04-03 | 2010-03-24 | 特里梅里斯公司 | 用于递送抗病毒肽治疗剂的新制剂 |
| CN101104635B (zh) * | 2007-04-30 | 2010-11-03 | 北京济普霖生物技术有限公司 | 一种从转基因牛乳中纯化重组人α-乳清白蛋白的方法 |
| CN101835801B (zh) | 2007-08-08 | 2014-09-10 | 诺维信生物制药丹麦公司 | 转铁蛋白变体和偶联物 |
| BRPI0817697A2 (pt) * | 2007-09-25 | 2015-04-07 | Trimeris Inc | Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo |
| JP4452324B2 (ja) * | 2008-03-31 | 2010-04-21 | 積水メディカル株式会社 | 精製血清アルブミン及び免疫学的測定方法 |
| MX2010012416A (es) * | 2008-05-15 | 2010-12-21 | R Tech Ueno Ltd | Composicion farmaceutica para el tratamiento del ojo seco y/o lesion corneal y conjuntival. |
| WO2009146320A1 (en) | 2008-05-27 | 2009-12-03 | Dmi Life Sciences, Inc. | Therapeutic methods and compounds |
| JP5711118B2 (ja) | 2008-06-24 | 2015-04-30 | テクニッシュ ウニヴェルジテート ミュンヘン | 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン |
| SG172789A1 (en) | 2009-02-11 | 2011-08-29 | Novozymes Biopharma Dk As | Albumin variants and conjugates |
| US20120315697A1 (en) | 2009-02-20 | 2012-12-13 | Ventria Bioscience | Cell Culture Media Containing Combinations of Proteins |
| DE102009013914B4 (de) * | 2009-03-19 | 2011-05-05 | Bruker Daltonik Gmbh | Kalibriersubstanzen für Atmosphärendruck-Ionenquellen |
| EP2427489B1 (en) * | 2009-05-07 | 2015-04-22 | Novozymes Biopharma DK A/S | Method of controlling o-linked glycosylation of antibodies |
| BR112012002709A2 (pt) | 2009-08-05 | 2019-04-30 | Pieris Ag | formulações de liberação controlada de muteínas de lipocalina |
| CA2771232A1 (en) * | 2009-08-20 | 2011-02-24 | Baxter International Inc. | Purification of vwf for increased removal of non-lipid enveloped viruses |
| RU2607374C2 (ru) | 2009-10-30 | 2017-01-10 | Новозаймс Байофарма Дк А/С | Варианты альбумина |
| EP3660510A3 (en) | 2009-12-07 | 2020-07-08 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target |
| AU2011207425A1 (en) * | 2010-01-25 | 2012-08-16 | Ventria Bioscience | Methods and compositions for improving protein production |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| HRP20190689T1 (hr) | 2010-06-08 | 2019-06-14 | Pieris Pharmaceuticals Gmbh | Muteini suznog lipokalina koji vežu il-4r alfa |
| EP3299386A1 (en) | 2010-08-16 | 2018-03-28 | Pieris Pharmaceuticals GmbH | Binding proteins for hepcidin |
| CA2810844C (en) | 2010-09-07 | 2017-03-21 | Dmi Acquisition Corp. | Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions |
| US9260492B2 (en) | 2010-11-15 | 2016-02-16 | Pieris Ag | Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3) |
| WO2012072806A1 (en) | 2010-12-02 | 2012-06-07 | Pieris Ag | Muteins of human lipocalin 2 with affinity for ctla-4 |
| PL221899B1 (pl) | 2011-05-06 | 2016-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Czysta albumina oraz sposób jej otrzymywania i detekcji |
| JP6247210B2 (ja) | 2011-07-05 | 2017-12-13 | アルブミディクス アクティーゼルスカブ | アルブミン製剤及び用途 |
| CA2846464A1 (en) | 2011-10-10 | 2013-04-18 | Ampio Pharmaceuticals, Inc. | Implantable medical devices with increased immune tolerance, and methods for making and implanting |
| ES2795803T3 (es) | 2011-10-10 | 2020-11-24 | Ampio Pharmaceuticals Inc | Tratamiento de artropatía degenerativa |
| HK1198812A1 (en) | 2011-10-28 | 2015-06-12 | Ampio Pharmaceuticals, Inc. | Treatment of rhinitis |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| US9572863B2 (en) | 2011-12-13 | 2017-02-21 | Pieris Pharmaceuticals Gmbh | Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors |
| MX2014010278A (es) | 2012-03-16 | 2015-03-05 | Novozymes Biopharma Dk As | Variantes de albumina. |
| US9522940B2 (en) | 2012-05-23 | 2016-12-20 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3 |
| US20140031527A1 (en) * | 2012-07-27 | 2014-01-30 | Csl Limited | Method for polishing albumin |
| CN105452290A (zh) | 2012-11-08 | 2016-03-30 | 诺维信生物制药丹麦公司 | 白蛋白变体 |
| EP3441400B1 (en) | 2012-11-19 | 2022-07-20 | Pieris Pharmaceuticals GmbH | Novel specific-binding polypeptides and uses thereof |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| JP6128677B2 (ja) * | 2013-02-05 | 2017-05-17 | 公立大学法人大阪市立大学 | 神経細胞の遊走障害を伴う疾患の判定方法及びその利用 |
| KR20150131151A (ko) | 2013-03-14 | 2015-11-24 | 다이이찌 산쿄 가부시키가이샤 | 피씨에스케이9에 대한 신규의 결합 단백질 |
| WO2014145729A2 (en) | 2013-03-15 | 2014-09-18 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| CN103694343B (zh) * | 2013-12-26 | 2016-05-25 | 扬州艾迪生物科技有限公司 | 一种从尿液中制备人血白蛋白的方法 |
| WO2015104406A2 (en) | 2014-01-13 | 2015-07-16 | Pieris Ag | Multi-specific polypeptide useful for localized tumor immunomodulation |
| EP3137186B1 (en) * | 2014-04-30 | 2021-01-27 | Novo Nordisk A/S | Methods for the purification of proteins using caprylic acid |
| US10774119B2 (en) | 2014-05-22 | 2020-09-15 | Pieris Pharmaceuticals Gmbh | Specific-binding polypeptides and uses thereof |
| EP4066836A1 (en) | 2014-08-18 | 2022-10-05 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| CN104628830A (zh) * | 2015-01-23 | 2015-05-20 | 深圳康泰生物制品股份有限公司 | 重组酿酒酵母表达HBsAg的制备工艺及其分离纯化工艺、HBsAg和乙肝疫苗 |
| AU2016212087B2 (en) | 2015-01-28 | 2019-11-07 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| CR20170425A (es) | 2015-02-18 | 2017-11-22 | Sanofi Sa | Nuevas proteínas específicas para pioverdina y pioquelina |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| CN114573680A (zh) | 2015-05-04 | 2022-06-03 | 皮里斯制药有限公司 | Cd137特异性的蛋白 |
| CA2980840A1 (en) | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| BR112017020961A2 (pt) | 2015-05-18 | 2018-07-10 | Pieris Pharmaceuticals Gmbh | muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação |
| RS64002B1 (sr) | 2015-05-18 | 2023-03-31 | Pieris Pharmaceuticals Gmbh | Anti-kancerski fuzioni polipeptid |
| US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| EP3115371A1 (en) | 2015-07-07 | 2017-01-11 | Sanofi | Fusion molecules |
| CA2988831A1 (en) | 2015-07-15 | 2017-01-19 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for lag-3 |
| CA2989966C (en) | 2015-08-20 | 2024-04-30 | Albumedix A/S | Albumin variants and conjugates |
| FR3040882A1 (fr) * | 2015-09-10 | 2017-03-17 | Lab Francais Du Fractionnement | Composition liquide d'albumine humaine a usage therapeutique |
| EA035586B1 (ru) | 2015-11-30 | 2020-07-10 | Пиерис Острелиа Пти Лтд. | Новые антиангиогенные слитые белки |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
| WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
| JP7146637B2 (ja) | 2015-12-22 | 2022-10-04 | アルブミディクス リミティド | 改善されたタンパク質発現株 |
| KR102050852B1 (ko) * | 2016-03-11 | 2019-12-03 | 주식회사 스템온 | 세포 리프로그래밍 장치 |
| CN110198952B9 (zh) * | 2016-08-17 | 2024-05-28 | 勃林格殷格翰国际公司 | 制备含有生物分子的高度浓缩的液体制剂的方法 |
| KR102573478B1 (ko) | 2016-10-04 | 2023-09-04 | 알부메딕스 리미티드 | 재조합 효모-유래 혈청 알부민의 용도 |
| WO2018087108A1 (en) | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| SG11201906509WA (en) | 2017-01-18 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| AU2018233184B2 (en) * | 2017-03-16 | 2022-06-16 | Evolve Biologics Inc. | Method for purification of albumin |
| DK3642343T3 (en) | 2017-06-20 | 2022-03-14 | Albumedix Ltd | Improved protein expression strains |
| IL277797B1 (en) * | 2018-04-12 | 2024-11-01 | Amgen Inc | Methods for making stable protein compositions |
| CN110563833A (zh) * | 2018-06-06 | 2019-12-13 | 中国计量科学研究院 | 一种人血白蛋白标准物质原料的制备方法及其产品和应用 |
| RS64343B9 (sr) | 2018-07-31 | 2023-11-30 | Pieris Pharmaceuticals Gmbh | Novi fuzioni protein specifičan za cd137 i pd-l1 |
| CN109734796B (zh) * | 2019-02-01 | 2022-04-15 | 广州蕊特生物科技有限公司 | 一种从溶血血清中分离白蛋白的工艺 |
| CN109776673B (zh) * | 2019-02-20 | 2022-03-29 | 天津理工大学 | 一种适合中试量产的高纯度牛血清白蛋白纯化工艺 |
| WO2020173897A1 (en) | 2019-02-26 | 2020-09-03 | Pieris Pharmaceuticals Gmbh | Novel fusion proteins specific for cd137 and gpc3 |
| CN110229229A (zh) * | 2019-07-10 | 2019-09-13 | 甘肃养泰和生物科技有限公司 | 一种从牛血浆中提取纯化细胞培养级牛血清白蛋白的生产方法及其应用 |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| JP2023527908A (ja) | 2020-06-05 | 2023-06-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | ４－１ｂｂをターゲティングする多量体免疫調節物質 |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| US12161777B2 (en) | 2020-07-02 | 2024-12-10 | Davol Inc. | Flowable hemostatic suspension |
| WO2022033525A1 (en) | 2020-08-11 | 2022-02-17 | Shenzhen Protgen Ltd. | Young and undamaged human serum albumin improves longevity of human |
| KR20230088914A (ko) * | 2020-10-30 | 2023-06-20 | 선전 프로트젠 엘티디. | 질환 치료에서 인간 혈청 알부민의 응용 |
| CN114885608A (zh) | 2020-12-08 | 2022-08-09 | 通化安睿特生物制药股份有限公司 | 纯化重组蛋白的方法 |
| CN112592399B (zh) * | 2020-12-15 | 2024-04-12 | 甘肃养泰和生物科技有限公司 | 一种从牛血清中分离牛血清白蛋白的制备方法及装置 |
| WO2022146917A1 (en) | 2020-12-28 | 2022-07-07 | Davol Inc. | Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent |
| EP4320141A1 (en) | 2021-04-08 | 2024-02-14 | Pieris Pharmaceuticals GmbH | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) |
| WO2022243341A1 (en) | 2021-05-18 | 2022-11-24 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for ox40 |
| CN113735963A (zh) * | 2021-09-10 | 2021-12-03 | 山东健通生物科技有限公司 | 一种重组人血清白蛋白纯化过程去除色素的方法 |
| CN114316088B (zh) * | 2021-12-22 | 2022-09-09 | 中国水产科学研究院黄海水产研究所 | 亲和树脂、制备方法及其在分离纯化藻蓝蛋白中的应用 |
| WO2024064713A1 (en) | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
| CN115677848A (zh) * | 2022-10-24 | 2023-02-03 | 通化安睿特生物制药股份有限公司 | 一种制备高纯度高稳定性蛋白质的方法 |
| CN116120392B (zh) * | 2023-04-18 | 2023-08-01 | 上海健士拜生物科技有限公司 | 聚体蛋白的纯化方法 |
| WO2025175123A1 (en) | 2024-02-16 | 2025-08-21 | Seagen Inc. | Methods of treating cancer using fusion proteins specific for cd137 and cd228 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9019919D0 (en) * | 1990-09-12 | 1990-10-24 | Delta Biotechnology Ltd | Purification of proteins |
| US2433905A (en) | 1943-11-01 | 1948-01-06 | Jr Walter L Hughes | Method for the crystallization of albumin and the preparation of protein products therefrom |
| AT317418B (de) * | 1972-06-16 | 1974-08-25 | Brigitte Panhofer | Verfahren zur Herstellung von intravenös beim Menschen anwendbarem Humanalbumin aus menschlichen Placenten |
| FR2190437B1 (enExample) | 1972-07-05 | 1975-08-08 | Merieux Inst | |
| CA1044537A (en) | 1973-05-09 | 1978-12-19 | Amf Incorporated | Filter medium and process |
| DE2537123A1 (de) * | 1975-08-20 | 1977-03-03 | New Zealand Inventions Dev | Verfahren zur herstellung von albumin |
| SE405549B (sv) * | 1975-10-09 | 1978-12-18 | Pharmacia Fine Chemicals Ab | Forfarande for isolering av albumin ur plasmaprodukter genom kromatografisk fraktionering |
| US4043997A (en) * | 1976-05-28 | 1977-08-23 | Cutter Laboratories, Inc. | Method for isolating albumin using insoluble supports coupled to a dye |
| US4075197A (en) * | 1976-09-20 | 1978-02-21 | Monsanto Company | Serum albumin production |
| IN150740B (enExample) | 1978-11-24 | 1982-12-04 | Hoffmann La Roche | |
| US4228154A (en) * | 1979-02-26 | 1980-10-14 | Armour Pharmaceutical Company | Purification of plasma albumin by ion exchange chromatography |
| US4222934A (en) * | 1979-04-12 | 1980-09-16 | American National Red Cross | Preparation of albumin using ethanol |
| GB2053926B (en) | 1979-07-20 | 1983-02-23 | Atkinson A | Albumin extraction by affinity chromatography |
| US4350156A (en) * | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| IL66614A (en) * | 1981-08-28 | 1985-09-29 | Genentech Inc | Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it |
| US4391801A (en) | 1981-10-29 | 1983-07-05 | Cutter Laboratories, Inc. | Plasma protein fraction substantially free of acetate ions |
| FR2543448A1 (fr) * | 1983-04-01 | 1984-10-05 | Rhone Poulenc Spec Chim | Procede de fractionnement du plasma |
| US4748120A (en) * | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
| DE3344656A1 (de) * | 1983-12-09 | 1985-06-13 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung einer serumproteinloesung |
| CA1286622C (en) * | 1986-04-28 | 1991-07-23 | Chokyun Rha | Method for clarifying and stabilizing cell culture media |
| JPS62294621A (ja) | 1986-06-13 | 1987-12-22 | Green Cross Corp:The | アルブミンの回収方法 |
| JPS6383100A (ja) * | 1986-09-26 | 1988-04-13 | Green Cross Corp:The | ヒト尿中アルブミンの製造方法 |
| US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
| IL88326A (en) | 1987-11-18 | 1993-03-15 | Gist Brocades Nv | Purification of serum albumin |
| US4990447A (en) * | 1988-06-24 | 1991-02-05 | Gist-Brocades Nv | Process for the purification of serum albumin |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| JP3554796B2 (ja) * | 1988-10-31 | 2004-08-18 | 三菱ウェルファーマ株式会社 | アルブミン製剤及びその製造方法 |
| US4891221A (en) * | 1988-11-23 | 1990-01-02 | Edward Shanborm | Whole blood antiviral process and composition |
| FR2648048B1 (fr) * | 1989-06-08 | 1994-06-03 | Lille Transfusion Sanguine | Procede de preparation de solutions d'albumine purifiee |
| GB8913586D0 (en) | 1989-06-13 | 1989-08-02 | Technicol Limited | A method of determining the glycosylated protein level of a sample and an apparatus for use in the method |
| JPH0768137B2 (ja) * | 1989-06-15 | 1995-07-26 | 株式会社ミドリ十字 | アルブミン製剤及びその製法 |
| SE500110C2 (sv) | 1989-06-27 | 1994-04-18 | Kabi Pharmacia Ab | Sätt att rena ett protein från därtill bundna flervärda metalljoner |
| JPH0671434B2 (ja) | 1989-09-18 | 1994-09-14 | 株式会社ミドリ十字 | ヒト血清アルブミンの製造方法 |
| US5250662A (en) * | 1989-10-05 | 1993-10-05 | Alpha Therapeutic Corporation | Albumin purification |
| CA2022165C (en) | 1989-10-05 | 1999-11-23 | Chong E. Chang | Albumin purification |
| ES2224094T3 (es) * | 1990-04-19 | 2005-03-01 | Bayer Corporation | Procedimiento para preparar seroalbumina normal (humana) esencialmente monomerica. |
| JP3230091B2 (ja) * | 1990-06-25 | 2001-11-19 | ウェルファイド株式会社 | ヒト血清アルブミンの着色抑制方法 |
| JP2982296B2 (ja) | 1990-11-19 | 1999-11-22 | 吉富製薬株式会社 | アルブミン含有水溶液の精製法 |
| JP2949846B2 (ja) | 1990-11-30 | 1999-09-20 | 吉富製薬株式会社 | アルブミン製剤の保存方法 |
| FR2672604B1 (fr) | 1991-02-07 | 1995-05-05 | Pasteur Merieux Serums Vacc | Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue. |
| US5284777A (en) | 1991-03-04 | 1994-02-08 | Isolab, Inc. | Combined glycated hemoglobin and immunoturbidometric glycated albumin assay from whole blood lysate |
| US5330901A (en) * | 1991-04-26 | 1994-07-19 | Research Corporation Technologies, Inc. | Expression of human serum albumin in Pichia pastoris |
| ES2141715T3 (es) * | 1991-07-12 | 2000-04-01 | Dsm Nv | Procedimiento para la purificacion de albumina de suero. |
| FR2686620B1 (fr) * | 1992-01-27 | 1995-06-23 | Rhone Poulenc Rorer Sa | Serum-albumine humaine, preparation et utilisation. |
| US5281582A (en) * | 1992-02-27 | 1994-01-25 | Alliance Pharmaceuticals, Corp. | Serum growth factor |
| US5440018A (en) * | 1992-05-20 | 1995-08-08 | The Green Cross Corporation | Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same |
| JP3360315B2 (ja) * | 1992-07-31 | 2002-12-24 | 三菱ウェルファーマ株式会社 | ヒト血清アルブミンの高度精製方法 |
| DE4226971C2 (de) | 1992-08-14 | 1997-01-16 | Widmar Prof Dr Tanner | Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte |
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| CN1055095C (zh) * | 1992-12-11 | 2000-08-02 | 上海莱士血制品有限公司 | 白蛋白的纯化方法 |
| CA2116385A1 (en) * | 1993-02-25 | 1994-08-26 | Akinori Sumi | Human serum albumin and process for producing the same |
| SE9301583D0 (sv) | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Yeast strain and methods for expressing heterologous proteins in yeast |
| JP3702474B2 (ja) | 1994-06-01 | 2005-10-05 | 三菱ウェルファーマ株式会社 | 血清アルブミン製剤の製造方法 |
| ES2211889T3 (es) * | 1994-08-31 | 2004-07-16 | Mitsubishi Pharma Corporation | Procedimiento para la purificacion de albumina de suero recombinante. |
| JPH09209303A (ja) | 1996-02-05 | 1997-08-12 | Hokkaido Supuritsuton Kogyo Kk | 舗装ブロック |
| AU4837996A (en) | 1996-02-29 | 1997-09-16 | Delta Biotechnology Limited | High purity albumin production process |
-
1995
- 1995-05-25 US US08/378,859 patent/US5728553A/en not_active Expired - Lifetime
-
1996
- 1996-02-29 CN CNB2006101006176A patent/CN100443499C/zh not_active Expired - Lifetime
- 1996-02-29 CA CA002220923A patent/CA2220923C/en not_active Expired - Lifetime
- 1996-02-29 EP EP00201960A patent/EP1031578B1/en not_active Expired - Lifetime
- 1996-02-29 CN CNB2004100575838A patent/CN100455597C/zh not_active Expired - Lifetime
- 1996-02-29 WO PCT/GB1996/000449 patent/WO1996037515A1/en not_active Ceased
- 1996-02-29 PT PT96904190T patent/PT828759E/pt unknown
- 1996-02-29 EP EP96904190A patent/EP0828759B1/en not_active Expired - Lifetime
- 1996-02-29 CN CNB961958243A patent/CN1198844C/zh not_active Expired - Lifetime
- 1996-02-29 KR KR1019970708469A patent/KR100566606B1/ko not_active Expired - Lifetime
- 1996-02-29 CN CN03127743A patent/CN100584857C/zh not_active Expired - Lifetime
- 1996-02-29 AT AT00201960T patent/ATE265469T1/de active
- 1996-02-29 AT AT96904190T patent/ATE198482T1/de active
- 1996-02-29 DK DK00201960T patent/DK1031578T3/da active
- 1996-02-29 US US08/952,558 patent/US6638740B1/en not_active Expired - Fee Related
- 1996-02-29 DE DE69611445T patent/DE69611445T2/de not_active Expired - Lifetime
- 1996-02-29 ES ES00201960T patent/ES2219257T3/es not_active Expired - Lifetime
- 1996-02-29 DE DE69632353T patent/DE69632353T2/de not_active Expired - Lifetime
- 1996-02-29 PT PT00201960T patent/PT1031578E/pt unknown
- 1996-02-29 ES ES96904190T patent/ES2156991T3/es not_active Expired - Lifetime
- 1996-02-29 JP JP53545796A patent/JP4040088B2/ja not_active Expired - Lifetime
- 1996-02-29 DK DK96904190T patent/DK0828759T3/da active
- 1996-02-29 KR KR1020047011825A patent/KR100543612B1/ko not_active Expired - Lifetime
- 1996-02-29 AU AU48380/96A patent/AU698409B2/en not_active Ceased
-
1997
- 1997-11-14 US US08/970,648 patent/US6034221A/en not_active Expired - Lifetime
- 1997-11-25 MX MX9709108A patent/MX9709108A/es unknown
-
2001
- 2001-03-29 GR GR20010400501T patent/GR3035651T3/el unknown
-
2002
- 2002-05-31 JP JP2002160250A patent/JP4037174B2/ja not_active Expired - Lifetime
- 2002-11-21 US US10/301,357 patent/US20030187226A1/en not_active Abandoned
-
2004
- 2004-06-22 US US10/873,504 patent/US7223561B2/en not_active Expired - Fee Related
-
2006
- 2006-07-04 JP JP2006184756A patent/JP4372772B2/ja not_active Expired - Lifetime
-
2007
- 2007-04-23 US US11/738,582 patent/US7601515B2/en not_active Expired - Fee Related
- 2007-07-30 JP JP2007197742A patent/JP4372813B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69632353T2 (de) | Hochreines Albumin, durch ein mehrstufiges Verfahren hergestellt | |
| JPH11509525A (ja) | 高純度アルブミンの製造方法 | |
| DE69331507T2 (de) | Verfahren zur Reinigung von menschlichem, rekombinantem Serumalbumin | |
| DE3876401T2 (de) | N-terminale fragmente von menschlichem serumalbumin. | |
| DE69202049T2 (de) | Verfahren zur reinigung von intaktem und korrekt gefaltetem igf-i. | |
| DE60217804T2 (de) | Fusionsprotein mit erhöhter in vivo Erythropoietinaktivität | |
| DE3726655A1 (de) | Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten | |
| DE19652713C2 (de) | Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher | |
| DE3650276T2 (de) | Proteinreinigung. | |
| DE69700843T2 (de) | Verfahren zur reinigung opazifierender kontrastmittel | |
| DE69303941T2 (de) | Verfahren zur Herstellung von hochreinem Fibrinogen | |
| DE69408677T2 (de) | Nickelfreier hämoglobin und verfahren zu seiner herstellung | |
| DE2718325C2 (de) | Leucinreiches 3,1-S-&alpha;&darr;2&darr;-Glykoprotein sowie dessen Verwendung | |
| WO1989001485A1 (fr) | Purification de peptides bruts par chromatographie liquide de preparation sous une pression moyenne | |
| HK1072436B (en) | Process of high purity albumin production | |
| AT398767B (de) | Verfahren zur reinigung eines rohpeptids mittels präparativer mitteldruckflüssigkeitschromatographie | |
| EP0219839A2 (de) | Derivat des Interleukin-2, seine Herstellung und Verwendung | |
| CH676987A5 (en) | Crude peptide purificn. by medium-pressure liq. chromatography |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVOZYMES DELTA LTD., NOTTINGHAM, GB |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVOZYMES BIOPHARMA UK LIMITED, NOTTINGHAM, GB |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVOZYMES BIOPHARMA DK A/S, BAGSVAERD, DK |